# A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers

> **NCT01818024** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 54 (actual)

## Conditions studied

- Respiratory Disorders

## Interventions

- **DRUG:** Single IV dose of GSK2862277
- **DRUG:** Matching placebo single dose IV infusion
- **DRUG:** Single IH dose of GSK2862277
- **DRUG:** Matching placebo single dose IH
- **DRUG:** Repeat IV dose of GSK2862277
- **DRUG:** Matching placebo repeat dose IV infusion
- **DRUG:** Repeat IH dose selected of GSK2862277 from Part 2
- **DRUG:** Matching placebo repeat dose IH

## Key facts

- **NCT ID:** NCT01818024
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-22
- **Primary completion:** 2013-10-25
- **Final completion:** 2013-10-25
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01818024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01818024, "A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01818024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*